NDA 209279 · Actelion
Tracleer
Bosentan · Oral
OrphanLast checked: Nov 20, 2026Latest source record: Oct 27, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2017
Sep 5, 2017
Approved uses
1
Original approval plus efficacy supplements
Registered trials
112
36 Phase 3, 6 recruiting
FAERS reports
50,359
42,531 serious, 15,990 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: RISKS OF HEPATOTOXICITY and EMBRYO-FETAL TOXICITY Because of the risk of hepatotoxicity, TRACLEER is available only through a restricted program called the Bosentan Risk Evaluation and Mitigation Strategy (REMS). Under the Bosentan REMS, prescribers, patients, and pharmacies must enroll in the program [see Warnings and Precautions (5.2) ] . WARNING: RISKS OF HEPATOTOXICITY and EMBRYO-FETAL TOXICITY See full prescribing information for complete boxed warning. TRACLEER is available only through a restricted distribution program called the Bosentan Risk Evaluation and Mitigation Strategy (REMS) because of the risk of hepatotoxicity ( 5.2 ): Elevations of liver aminotransferases (ALT, AST) and liver failure have been reported with TRACLEER ( 5.1 ). Measure liver aminotransferases prior to initiation of treatment and then monthly ( 2.1 , 5.1 ). Discontinue TRACLEER if...
What it is approved for
From the label in effect Nov 17, 2025.
TRACLEER is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1): in adults to improve exercise ability and to decrease clinical worsening. Studies establishing effectiveness included predominantly patients with WHO Functional Class II-IV symptoms and etiologies of idiopathic or heritable PAH (60%), PAH associated with connective tissue diseases (21%), and PAH associated with congenital heart disease with left-to-right shunts (18%) [see Clinical Studies (14.1) ] . in pediatric patients aged 3 years and older with idiopathic or congenital PAH to improve pulmonary vascular resistance (PVR), which is expected to result in an improvement in exercise ability. TRACLEER is an endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1): in adults to improve exercise ability and to decrease clinical worsening. Studies establishing effectiveness included predominantly patients with WHO Functional Class II-IV symptoms and etiologies of idiopathic or heritable PAH (60%), PAH associated with connective tissue diseases (21%), and PAH associated with congenital heart disease with left-to-right shunts (18%) ( 1 ). in pediatric patients aged 3 years and older with idiopathic or congenital PAH to improve pulmonary vascular resistance (PVR), which is expected to result in an improvement in exercise ability ( 1 ).
Mechanism: Bosentan is a specific and competitive antagonist at endothelin receptor types ET A and ET B . Bosentan has a slightly higher affinity for ET A receptors than for ET B receptors. The clinical impact of dual endothelin blockage is unknown. Endothelin-1 (ET-1) is a neurohormone, the effects of which are mediated by binding to ET A and ET B receptors in the endothelium and vascular smooth muscle. ET-1 concentrations are elevated in plasma and lung tissue of patients with PAH, suggesting a pathogenic role for ET-1 in this disease.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- TRACLEER · BOSENTAN 32MG · TABLET, FOR SUSPENSION, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Bosentan" as an intervention, any sponsor and status, largest first.
- Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial HypertensionPivotal-lookingActive, not recruiting
ActelionJohnson & Johnson (Janssen) (JNJ)
NCT04273945 · 935 participants · Start Jun 30, 2020 · Primary completion Oct 7, 2025
Drug: Macitentan 10 mg; Macitentan 37.5 mg and 2 more · For: Pulmonary Arterial Hypertension
Sites: Phoenix, Arizona; Scottsdale, Arizona; La Jolla, California · 274 sites in all
- BUILD 3: Bosentan Use in Interstitial Lung DiseasePivotal-lookingCompleted
ActelionJohnson & Johnson (Janssen) (JNJ)
NCT00391443 · 616 participants · Start Feb 2007 · Primary completion Feb 2010
Drug: Bosentan; Placebo · For: Idiopathic Pulmonary Fibrosis
- Effects of the Combination of Bosentan and Sildenafil Versus Sildenafil Monotherapy on Pulmonary Arterial Hypertension (PAH)Pivotal-lookingCompleted
ActelionJohnson & Johnson (Janssen) (JNJ)
NCT00303459 · 334 participants · Start May 2006 · Primary completion Dec 2013
Drug: bosentan; placebo · For: Pulmonary Arterial Hypertension
- Endothelin Receptor Function and Acute StressPivotal-lookingActive, not recruiting
Augusta UniversityAcademic, hospital or other
NCT02116335 · 320 participants (planned) · Start Jun 2015 · Primary completion Dec 2025
Drug: Bosentan; Placebo · For: Hypertension
Sites: Augusta, Georgia
- Safety and Efficacy Study of Sitaxentan Sodium (Thelin™) in Patients With Pulmonary Arterial HypertensionPivotal-lookingCompleted
Encysive PharmaceuticalsIndustry
NCT00080457 · 240 participants · Start May 2003
Drug: sitaxsentan sodium · For: Pulmonary Hypertension
Sites: Houston, Texas
- A Study of Patients Having Pulmonary Hypertension Associated With Sickle Cell Disease and Completing an ASSET StudyPivotal-lookingTerminated
ActelionJohnson & Johnson (Janssen) (JNJ)
NCT00360087 · 236 participants · Start Mar 2006 · Primary completion Aug 2007
Drug: Bosentan · For: Pulmonary Hypertension; Sickle Cell Anemia
- A Clinical Trial to Evaluate MK-4208/Embibatinib in Healthy Adult Participants (MK-4208-001/Embibatinib-1014)Pivotal-lookingCompleted
Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Industry
NCT07838987 · 196 participants · Start Dec 21, 2023 · Primary completion Jun 30, 2026
Drug: Embibatinib; Rabeprazole and 10 more · For: Healthy
Sites: Millcreek, Utah
- Efficacy and Safety of Oral Bosentan on Healing/Prevention of Digital (Finger) Ulcers in Patients With SclerodermaPivotal-lookingCompleted
ActelionJohnson & Johnson (Janssen) (JNJ)
NCT00077584 · 188 participants · Start Oct 2003 · Primary completion Mar 2005
Drug: Bosentan 62.5 mg; Bosentan 125 mg and 1 more · For: Digital Ulcers; Systemic Sclerosis
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- death9,335
- dyspnoea6,016
- pneumonia2,701
- pulmonary arterial hypertension2,297
- fatigue2,269
- headache2,236
- nausea2,073
- diarrhoea2,009
- condition aggravated1,875
- dizziness1,777
- malaise1,716
- fall1,575
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 691 |
| 2005 | 461 |
| 2006 | 514 |
| 2007 | 360 |
| 2008 | 456 |
| 2009 | 567 |
| 2010 | 4,019 |
| 2011 | 4,231 |
| 2012 | 4,933 |
| 2013 | 3,952 |
| 2014 | 4,429 |
| 2015 | 4,425 |
| 2016 | 2,999 |
| 2017 | 2,710 |
| 2018 | 2,551 |
| 2019 | 2,554 |
| 2020 | 2,592 |
| 2021 | 1,570 |
| 2022 | 1,880 |
| 2023 | 1,878 |
| 2024 | 950 |
| 2025 | 887 |
| 2026 | 749 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Tracleer (Bosentan)
2024 spending
$13.6M
Beneficiaries
107
1,062 claims
Per beneficiary
$127,366
$205.54 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $33,833,038 |
| 2021 | $25,687,163 |
| 2022 | $18,513,093 |
| 2023 | $15,070,482 |
| 2024 | $13,628,164 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Tadalafil therapy for pulmonary arterial hypertension.
Galiè N, Brundage BH, Ghofrani HA, et al. · Circulation 2009 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Treatment of pulmonary arterial hypertension in patients with connective tissue diseases: a systematic review and meta-analysis.
Erdogan M, Esatoglu SN, Kilickiran Avci B, et al. · Intern Emerg Med 2024 · Systematic Review, Meta-Analysis
- Oral sildenafil versus bosentan for treatment of persistent pulmonary hypertension of the newborn: a randomized controlled trial.
Kallimath A, Deshpande S, Singh P, et al. · BMC Pediatr 2024 · Randomized Controlled Trial, Comparative Study
- Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial.
McLaughlin VV, Benza RL, Rubin LJ, et al. · J Am Coll Cardiol 2010 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Gateways to clinical trials.
Bayes M, Rabasseda X, Prous JR · Methods Find Exp Clin Pharmacol 2006 · Clinical Trial
- Comparative Effectiveness of Oral Medications for Pulmonary Arterial Hypertension.
Igarashi A, Inoue S, Ishii T, et al. · Int Heart J 2016 · Systematic Review
Sponsor: Johnson & Johnson (Janssen)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.